Singapore: Singapore-based Vela Diagnostics has emerged as a new global player in the in vitro diagnostics market. The Singapore-headquartered group, which has already opened sites in New Jersey and Hamburg, said its menu of workflow systems and test kits will be launched progressively from Q3 2012.

"VelaDx stands for a broad and nimble menu of products in Molecular PCR-based diagnostics," said the Group's CEO Michael Tillmann. "Our automated workflow will enable hospitals and labs to handle a broader range of tests on a single platform. Lab professionals will be able to do more, faster but with less complexity and higher efficiency."

The company will provide an integrated automated RNA/DNA extraction and detection workflow on Vela's own Sentosa system. VelaDx tests will offer more than 30 tests grouped in areas including Microbiology, Oncology and Respiratory Diseases.

VelaDx provides a broad menu of molecular diagnostic tests, consolidated on its automated Sentosa workflow system. The group was incorporated by an industry experienced management team in 2011 with the vision of providing in-vitro diagnostic solutions for customers to achieve improved patient management.